17/04/2019
Marie Skłodowska-Curie Actions

INITIATE, H2020-MSCA-ITN-2018: 15 Early-Stage Researcher (ESR) 3-year positions


  • ORGANISATION/COMPANY
    Institutions across Europe in the INITIATE ITN network
  • RESEARCH FIELD
    Biological sciencesOther
    Medical sciencesOther
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    18/08/2019 00:00 - Europe/Athens
  • LOCATION
    Multiple locations, see work locations below.
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    36-40
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • MARIE CURIE GRANT AGREEMENT NUMBER
    813343

Applications are invited for 15 Early Stage Researcher (ESR) to be funded by the Marie-Sklodowska-Curie Innovative Training Network “INITIATE”  within the Horizon 2020 Programme of the European Commission.

INITIATE (Innate-Immunometabolism as Antiviral Target) is an Innovative Training Network funded by the European Commission and brings together world leaders in virology, inflammation, innate immunity and immunometabolism with the aim to educate a new generation of research scientists with interdisciplinary expertise in virology, immunology and immunometabolism.

Candidates

We are looking for talented and highly motivated early career researchers educated in biology, infection & immunity, biochemistry or related subjects and experience in cellular biology, (bio)chemistry, immunology and/or virology. We expect dedication and enthusiasm for experimental research, combined with scientific curiosity and the capacity to teamwork in an interdisciplinary environment. Positions are open from August 1st  2019, until the positions are filled (at the latest January 1st 2020 ) and ESRs will be based in the Netherlands, Ireland, Norway, Sweden, Austria, France or Italy.

Admission criteria

Candidates must have not been awarded a doctoral degree and be in the first four years of their research career. Candidates must have excellent proficiency in written and spoken English (at least level B2) and fulfil the specific University recruitment criteria of each position. Candidates can be of any nationality but need to demonstrate mobility in terms of moving  from one country to another when taking up their appointment. Importantly, candidates must not have resided or carried out their activities - work, studies, etc.- in the country of their host organization for more than 12 months in the 3 years immediately before August 1st 2019.

How to Apply:

Candidates can apply for a maximum of five positions; for each position, they must submit an application to the project coordinator (initiate@erasmusmc.nl) according to the procedures described in each project description. Applicants must include their CV, detailed academic transcripts in the form of certified copies of all undergraduate level certificates, a list of research-related methodological skills, a list of training experiences abroad, a motivation letter and three reference letters from previous professors or mentors. Each applicant will be notified of the final of their application. Applications must be send to: initiate@erasmusmc.nl.

POSITIONS

Project 1

Primary Supervisor: Prof. A. Bowie, Trinity College Dublin, Ireland

Title: Exploring the role of mitochondria and metabolism in human inflammasome activation by RNA viruses.

PROJECT: Inflammasomes are multiprotein complexes formed after the sensing of pathogens or cellular insults by members of the nucleotide-binding domain and leucine-rich repeat (LRR)-containing (NLR) family, such as NLRP3, and the pyrin and HIN domain (PYHIN) family, such as AIM2. Inflammasomes activate caspase-1 which leads to the maturation and secretion of interleukin 1 beta (IL-1β) and of IL-18, and also to the induction of pyroptosis, a form of cell death. Inflammasomes such as NLRP3 represent an important, but often poorly understood, component of the human innate immune response to RNA viruses, including respiratory syncytial virus (RSV) and influenza virus (IAV). Almost all of the mechanistic insights into how inflammasomes are activated, cause cytokine release, and regulate cell death have come from studies in mouse cells. For example, we have shown that after NLRP3 inflammasome activation in mouse bone marrow derived macrophages (BMDMs), mitochondrial depolarisation is required to cause maximal pyroptosis, but is not required for IL-1β release. Numerous studies have suggested roles for the mitochondria in inflammasome regulation in mouse cells, while other recent reports suggest that altered metabolism in macrophages is required for optimal inflammasome-dependent IL-1β production. We have developed biochemical tools and used CRISPR/Cas9 technology to study inflammasome activation in human cells. The aim of this project is to determine the role of mitochondrial function and metabolism in inflammasome activation and regulation after IAV and RSV infection of human cells (both monocytes and primary human epithelial cells). The project will also determine whether RNA virus inflammasome activation is altered in epithelial cells from asthma and/or COPD patients. Overall this project will reveal insights into the host-pathogen interface between RNA viruses and human cells, which will increase our understanding of inflammation during viral infections.

Job Detail

Type of Contract: Temporary (36 months); Status: Full-time  (40 hours/week)

Specific Requirements for the project

Primary honours degree in Biochemistry, Virology, Immunology or related discipline.

Organisation/Institute

Website: https://www.tcd.ie/research/profiles/?profile=agbowie

 

PROJECT 2

Primary supervisor: Prof. E. Snijder, LUMC, Leiden, The Netherlands

Title: To define innate immune- and lipid metabolism changes associated with viral replication organelles.

PROJECT: Replication organelles (ROs) are elaborate membranous structures induced in the cytosol of cells during positive strand RNA virus infections. Our long-term studies have suggested that ROs act to provide a microenvironment for efficient viral RNA replication, while also shielding viral RNA replication products and intermediates from cytosolic innate immune sensors. Whereas their ultrastructure has been studied in detail, very little is known about how ROs influence innate immune sensing and signaling, and cellular (lipid) metabolism. Since all +RNA viruses induce such structures, such knowledge could provide important new clues for more general antiviral strategies.  In this project we will attempt to understand if and how the innate immune system is able to attack viral ROs induced by nidoviruses such as MERS-CoV and equine arteritis virus (EAV).We recently published the first data indicating that ROs are indeed attacked by the type I IFN branch of the innate immune response. We will furthermore investigate the crosstalk between RO formation, innate immune responses and (lipid) metabolism during infection.  This ESR will use state-of-the-art molecular cloning techniques, and advanced electron microscopy methods, as well as CRISPr/Cas9 gene editing and RNA seq analyses in order to dissect innate immune- and metabolic factors involved in the hypothesized crosstalk. In collaboration with Prof. L. O’Neill at Trinity College Dublin in Ireland the ESR will use Seahorse technology for analysis of metabolic changes in cells that form viral ROs. Also, the influence of viral RO formation on the STING-mediated pathways will be investigated in collaboration with Stimunity in France. 

Job Detail

Type of Contract: Temporary (48 months); Status: Full-time (36 hours/week)

Specific Requirements for the project

Prospective PhD candidates have a MSc in Biology, Biomedical Sciences, or a related field of study. They have strong knowledge of infectious diseases and the immune system and are highly motivated to perform ground-breaking research at the international forefront at the cross-roads of these areas.

Organisation/Institute

Website: https://www.lumc.nl/org/mm/medewerkers/snijder?setlanguage=English&setcountry=en

 

PROJECT 3

Primary Supervisor:  Prof. Marit W. Anthonsen, Norwegian University of Science and Technology, Trondheim, Norway

Title: Changes in metabolic pathways associated with type III IFN-mediated signalling by pneumoviruses in mucosal cells

PROJECT: Interferons (IFNs) are produced in response to virus infection and induce an antiviral state in virtually all cell types. In addition to upregulating the transcription of genes that inhibit virus replication, IFNs also act to orchestrate the adaptive immune response to virus infection, important for vaccine strategies. Recently a new family of antiviral cytokines, the type III IFNs, has been identified. These IFNs are critical for the antiviral defense at mucosal surfaces, such as the airways, but the induction and action of type III IFNs are poorly understood. The cellular response to Pneumovirus involves changes in the assembly and activation states of proteins that are located at mitochondria, peroxisomes and cytoplasmic stress granules. Recent evidence has shown that bacteria is able to affect metabolism downstream of pathogen recognition. Likewise, the synthesis and effects of type I IFN depend on specific metabolic changes. However, the metabolic changes regulating type III IFN induction and action are not known. The purpose of this project is to investigate how Pneumovirus affects cellular metabolism that drives type III IFN expression and if peroxisomes and stress granules, metabolic compartments regulating antiviral defense mechanisms, are involved in the process. Moreover, we will determine if boosting the innate immune protein STING can change host metabolism for improved antiviral effects. For this purpose we will make use of Seahorse technology and RNA sequencing to determine changes in metabolic pathways, chemical inhibitors and CRISPR/Cas technology /RNA interference to target metabolic pathways, confocal microscopy to study compartmentalized signaling, and STING-activating virus-like particles to trigger innate immune signaling.  

Job Detail

Type of Contract: Temporary (36months); Status: Full-time (37,5 hours/week)

Specific Requirements for the project

Prospective PhD candidates have a MSc in Biology, Biomedical Sciences, or a related field of study. They have strong knowledge of infectious diseases and the immune system and are highly motivated to perform ground-breaking research at the international forefront at the cross-roads of these areas.

Organisation/Institute

website: https://www.ntnu.edu/employees/marit.w.anthonsen

 

PROJECT 4

Position is filled

 

PROJECT ESR 5

Primary supervisor: Prof. R. Fouchier, ErasmusMC, Rotterdam, The Netherlands

Title: The impact of influenza virus and Pneumovirus proteins on immunometabolism pathways

PROJECT: Viral infections can remodel immunometabolic pathways, especially glycolysis, in immune cells. However, limited information is available on this interaction for viruses causing acute respiratory infections, such as the Influenza virus. ESR5 will investigate how respiratory viruses, with a focus on the Influenza virus, interact with the immune-metabolism pathways of the host and how this interaction impacts viral replication. ESR5 will use Influenza virus proteins and genomic motifs to study this interaction using reverse genetics approaches, virological  techniques,  proximity labelling techniques , mass spectrometry, immunoprecipitation and immune assays. In addition, ESR5 will use CRISPr/Cas technology to knock down –if not lethal- expression of  identified host proteins in relevant cells for more detailed studies. In collaboration with Prof. L. O’Neill at Trinity College Dublin, ESR5 will analyse how the interaction between metabolism enzymes and viral-derived proteins impacts the phenotype of innate immune cells and their overall metabolism profile.  In collaboration with Dr. N. Manel at Stimunity in France, ESR5 will investigate the influence of STING stimulation on the interaction of the influenza virus with immunometabolic profiles.

Job Detail

Type of Contract: Temporary (48 months); Status: Full-time (38 hours/week)

Specific Requirements for the project

Prospective PhD candidates have a MSc in Biology, Biomedical Sciences, or a related field of study. They have strong knowledge of infectious diseases and the immune system and are highly motivated to perform ground-breaking research at the international forefront at the cross-roads of these areas.

Organisation/Institute

Website: www6.erasmusmc.nl/viroscience/research/researchers/ron_fouchier

 

PROJECT 6

Primary Supervisor:  Prof. L. O’Neill, Trinity College Dublin, Ireland

Title: Unravelling the effect of Pneumovirus and Influenza virus components on innate immune cell metabolism.

PROJECT : Innate immune cell activation causes a metabolic reprograming leading to accumulation of intracellular metabolites and modulation of inflammation, but the impact of viral infections on such process is poorly understood. The aim of this project is to analyse whether interaction with Pneumovirus and Influenza virus (IAV) proteins and RNA sensing through PRRs can alter the metabolic profile of innate immune cells, and to elucidate the downstream effector mechanisms being triggered. Ligands for multiple PRRs mimicking +RNA viruses, such as poly I:C and dsRNA, will be tested in this context. The outcome will be compared to the one of lipopolysaccharide (LPS)-Toll-like receptor (TLR)-4 binding, a well-known inducer of aerobic glycolysis in macrophages. Expression of metabolic enzymes and nutrient carriers will be analysed by qPCR and western blotting, with a particular focus on pyruvate kinase M2 isoform (PKM2) and stabilisation of hypoxia-induced factor-1a (HIF-1a), key drivers of TLR4-induced metabolic reprogramming in macrophages. Levels of intracellular metabolites such as succinate and itaconate will be measured by mass spectrometry, while qPCR and ELISAs will be used to quantify the production of inflammatory cytokines. To determine metabolic reprogramming, ESR6 will use the Seahorse technology. At ErasmusMC and in collaboration with ESR5, ESR6 will further investigate the specific impact of IAV and Pneumovirus infections on the phenotype and the metabolic profile of innate immune cells using the combined expertise of ErasmusMC(virology) and Trinity College Dublin (immunometabolism), while at AstraZeneca ESR6 will use the expertise of AstraZeneca to determine metabolic reorganisation in response to these virus infections in primary epithelial cells and the role of kinases such as MEK/ERK in this context. Overall, this project will highlight the possible modulation of immune and epithelial cell metabolism by viruses as part of viral mechanism of action. The project may identify novel metabolic-related pathways to be targeted in viral infections.

Job Details

Type of Contract: Temporary (36 months); Status: Full-time (40 hours/week)

Specific Requirements for the project

The candidate should have a primary degree in Immunology, Biochemistry or related subjects.

Organisation/Institute

Website: https://www.tcd.ie/Biochemistry/people/laoneill/

 

PROJECT 7

Primary supervisor: Dr. B. van den Hoogen, Erasmus MC, Rotterdam, The Netherlands

Title: To determine the role of Pneumovirus infection in regulation of MAVS signalling and its effect on immune- and metabolic pathways.

PROJECT: For respiratory viruses such as the Human Metapneumovirus (HMPV) , a member of the Pneumoviridae family, little is known about their interaction with the immunometabolism pathways. Elucidating knowledge on this interaction could lead to a rational design of antiviral therapies. Data so far, suggest that the M22 protein of HMPV is responsible for subverting the innate immune response by interfering withs MAVS signlalling , but other proteins and other pathways might also be involved in the mechanism. MAVS not only plays a pivotal role in the induction of antiviral and inflammatory pathways, but is also involved in the coordination of apoptotic and metabolic pathways.

Using our expertise on the molecular virology of HMPV, and a wide set of molecular, biochemical, virological and immunological techniques, ESR7 will  determine the role of the Pneumovirus M2.2 protein, as well as other viral proteins, in the interaction with innate immune- and metabolic pathways, with a focus on MAVS signalling. Cells knocked-down cellular factors of interest, made with CRISPr/Cas technology, will be used to further analyse the interaction and the effect on viral replication and immune-and metabolic profiles of infected cells.

In collaboration with Prof. A. Bowie at Trinity College in Dublin, ESR7 will determine the interaction of (specific proteins) of Pneumoviruses with the innate immune, inflammatory and metabolic pathways in more detail. In collaboration with Dr. K. Pardalli at AstraZeneca in Sweden, ESR7 will determine whether pneumovirus inflammasome activation is altered in primary human lung epithelial cells from asthma and/or COPD patients.

Job Detail

Type of Contract: Temporary (48 months): Status: Full-time (38 hours/week)

Specific Requirements for the project

Prospective PhD candidates have a MSc in Biology, Biomedical Sciences, or a related field of study. They have strong knowledge of infectious diseases and the immune system and are highly motivated to perform ground-breaking research at the international forefront at the cross-roads of these areas.

Organisation/Institute

Website: www6.erasmusmc.nl/viroscience/research/researchers/vandenhoogen/

 

PROJECT 8

Position is filled.

PROJECT 9

Primary Supervisor: Prof. J. Hiscott, Istituto Pasteur-Rome, Italy

Title: Effect of Influenza virus infection on Nrf2 activation of the oxidative stress response

PROJECT: The ESR will investigate the influence of influenza virus infection and specific viral proteins on the role of oxidative stress responses in regulation of immune- and metabolic responses. These studies will focus on nuclear factor erythroid 2-related factor 2 (Nrf2), a global transcriptional regulator of the anti-oxidant gene network response, and the maintenance of redox homeostasis through the control of basal and induced expression of an array of antioxidant enzymes. It is our hypothesis that these redox regulatory checkpoints are activated by influenza infection to inhibit the innate antiviral response and to facilitate virus replication.  Biochemical and molecular techniques, coupled with transcriptomic analysis and primary monocyte cell isolation will be used to measure ROS generation, mitochondrial depolarization and the generation of metabolites derived from the Krebs cycle, including succinate and itaconate, in terms of the reciprocal relationship between antioxidant Nrf2 and IFN regulatory networks. The effect of IAV infection, and individual viral proteins, on the overall metabolic profile of infected cells will be studied using Seahorse XF-24 technology. To investigate the mechanism of modulation in more detail, lung epithelial cells, macrophages and dendritic cells will be knocked-down for Nrf2 and other regulatory proteins, using CRISPr/Cas technology, and the consequence of ablation of Nrf2 on IAV replication kinetics, ROS production and metabolic profiles will be determined. These studies will provide: i) In depth understanding of the relationships between oxidative stress modulation, Nrf2-driven antioxidant responses and the regulation of the antiviral pathways directed against IAV infection; ii) Identification of metabolic products to modulate the Nrf2-IFN axis and impact on IAV pathogenesis. In collaboration with Dr. A. Bowie at TCD.

Job Details

Type of Contract: Temporary (36 months): Status:  Full-time (40 hours/week)

Specific Requirements for the project

The candidate should have a primary degree in Immunology, Biochemistry or related subjects.

Organisation/Institute

Website: http://www.istitutopasteur.it/wp-content/uploads/Hiscott-Profile-2015-IP-Rome.pdf

http://www.istitutopasteur.it/content/hiscott-john

 

PROJECT 10

Primary Supervisor: Prof. A. Santoni, Istituto Pasteur-Rome, Italy

Title: How innate lymphoid cells modulate inflammation by targeting STAT4

PROJECT: Innate lymphoid cells (ILCs) comprise specialized cytokine producer cells, which ensure barrier integrity and provide protection against bacterial and viral infections. Despite their recognized similarity with T cells, ILCs are endowed with distinctive features, including lack of antigen requirement for activation and an emerging role in regulation of metabolic homeostasis. However, the molecular mechanisms underlying ILC effector functions and their specific role in the context of an intact T cell response are still undisclosed. Members of the Signal Transducer and Activator of Transcription (STAT) family are important mediators for ILC homeostasis and effector functions. Due to the relevance of STAT4 signaling during viral infection and inflammation, targeting this pathway represents an attractive therapeutic strategy for several diseases. Preliminary results from our laboratory show a broad expression of STAT4 in ILCs expressing natural cytotoxicity receptors (NCR+ILCs), and evidence for a role of STAT4 expression by innate cells during inflammation. We hypothesize that STAT4 regulates transcriptomic modules in ILCs that are critically important in the outcome of infections, inflammation-driven diseases, and metabolic homeostasis.

The ESR will generate a novel mouse strain with selective STAT4 deletion in NCR+ILCs. These mice will be tested for ability to clear influenza virus A (IAV) infection. Also in the inflammation setting of EAE colitis (induced by administration of dextran sulfate sodium in the drinking water) or colitis-induced colorectal cancer, ILC populations will be evaluated by polychromatic flow cytometry. Cutting-edge next-generation sequencing technologies will be used to define STAT4-dependent transcriptional modules in ILCs. Bioinformatics analyses will be performed to unravel novel protective and/or pathogenic pathways in ILCs. In collaboration with Astra Zeneca, ESR10 will evaluate the role of STAT4 signaling in human ILCs. Taking advantage of the local expertise on manipulation of human ILCs, the STAT4 gene will be targeted using CRISPr/Cas9 system and ILC functions and gene expression profiles will be assessed.  In collaboration with Dr. Kikkert at LUMC, ESR10 will evaluate the relevance of ILCs and STAT4 signaling in the context of coronavirus infections (MHV and/or MERS-CoV) using the STAT4 conditional knock-out mice made in the project.

Job Details

Type of Contract: Temporary (36 months): Status: Full-time (40 hours/week)

Specific Requirements for the project

The candidate should have a primary degree in Immunology, Biochemistry or related subjects.

Organisation/Institute

Website: www.istitutopasteur.it

 

PROJECT 11

Primary supervisor: Dr. K. Pardalli, AstraZeneca, Gothenburg, Sweden

Title: Elucidating the effects of IFNs in the plasticity of innate immune cells

Talk about the SET or Business area

You will be working in two very competitive research facilities, the AstraZeneca Gothenburg site and Karolinska Institute in Stockholm.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines for some of the world’s most serious diseases. We're proud to have a unique workplace culture that inspires innovation and collaboration. We believe in the potential of our people and you’ll develop beyond what you thought possible. The new R&D BioPharmaceuticals organisation brings together research and development teams, from discovery through to late-stage development for Cardiovascular, Renal & Metabolic (CVRM), Respiratory, Inflammatory and Autoimmune (RIA) therapy areas, and opportunistically for Microbial Sciences and Neuroscience. You will join an agile environment, with a culture that is science and patient-focused. AZ’s Early RIA mission is to understand disease mechanisms at the molecular level, identify the most effective target and the right patient population, and close the gap between bench science and bedside clinical practice.

Karolinska Institutet is one of the world´s leading medical universities. Its mission is to contribute to the improvement of human health through research and education. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. It accounts for over 40 % of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. The Mjösberg group at KI studies the development, regulation and function of a particular immune cell, innate lymphoid cells (ILCs), in humans, and how these cells contribute to pathology in mucosal organs such as the lung and gut. The studies are translational as they involve advanced basic molecular and cellular immunological investigations of precious human tissue samples to discover novel disease mechanisms and therapy targets in inflammatory bowel disease, colorectal cancer, allergy and asthma. The group is internationally recognized as a leader in the field through several high impact publications in recent years (Nat Immunol 2016, JACI 2018, JACI 2018). The student will be a part of the Center for Infectious Medicine (CIM), Karolinska Institutet, which is a nationally leading and internationally competitive center for human translational immunology and infectious diseases research. The center consists of approximately 25 graduate students and 20 postdocs organized around 17 independent research groups, which has fostered many young and competitive researchers.

This project aims in understanding the mechanism by which virally induced factors such as IFNs and alarmins affect the plasticity and function of ILCs with particular focus on the role for eicosanoid production in ILCs. Furthermore, we want to elucidate whether ILCs can be infected by respiratory viruses, and the effect this might have in the phenotype, plasticity and metabolic signature of ILCs. In addition, this project aims to determine alterations in ILC frequency and function during novel biological treatment of asthma patients, potentially providing predictive tools for therapeutic response. Increased understanding of ILCs in asthma can help us identify novel targeting strategies to modulate the immunopathology of respiratory diseases and result in novel treatments that can not only address symptoms but modify and cure the underlying cause of disease.

Job Detail

Type of Contract:Temporary (36 months): Status: Full-time (40 hours/week)

Specific Requirements for the project

We are looking for a motivated student with a strong commitment to basic and/or translational research, who:

  • Is eligible for MSCA-ETN funding (see eligibility criteria).
  • Has a degree in cell biology, molecular/cell biology, biomedical sciences, immunology or related disciplines.
  • Has excellent experimental and analytical skills in cellular and molecular biology
  • Possesses hands on experience working with human immune cells, and basic cellular and molecular biology methods
  • Strong scientific background and interest in immunology and/or cell metabolism
  • Excellent organizational, communication and team-player skills with strong English knowledge in both oral and writing.
  • Enthusiastic, highly self-motivated and with the ability to function independently

Organisation/Institute

Website: https://www.astrazeneca.com/our-company/our-people/katerina-pardali.html

We are interviewing continuously, welcome with your application already today and no later than September 15th, 2019.

For more information about life in Gothenburg visit www.movetogothenburg.com

 

PROJECT 12

Primary supervisor: Dr. A. Bergthaler, The Research Center for Molecular Medicine (CeMM), Vienna, Austria

Title: Investigation of cytokine-induced metabolic rewiring of the liver in chronic viral infections

PROJECT: Inflammatory processes are tightly linked to metabolic pathways including secreted metabolites and cytokines. The liver is the central organ for metabolism and a hotspot for receiving, processing and distributing local and systemic signals. Yet, comparatively little is known about the metabolic-inflammatory crosstalk at the whole organism level. The proposed PhD project will characterize and delineate interconnected pathophysiological processes with a primary focus on the liver. Systems-level and hypothesis-driven approaches are integrated to identify novel regulatory nodes between metabolism and inflammation. The project will benefit from the combination of benchmark mouse models for chronic infection, cutting-edge technologies such as viral reverse genetics, RNA-seq, metabolomics and metabolite tracing and a multi-pronged focus on systemic immuno-metabolism in vivo. Together with primary cell culture systems and bioinformatic integration of available datasets from other animal models and patients through collaborations and/or the public domain, this project is expected to unravel key parts of the complex interplay between innate cytokine signaling and liver metabolism, which in turn may affect adaptive CD8 T cells and other immune effector cells. Elucidation of the pathophysiological roles of such novel immunoregulatory networks will provide an in-depth mechanistic understanding of pathogen control, inflammation and tissue pathology. This may result in the identification of novel therapeutic targets to ameliorate and/or prevent immunopathologies in infectious and inflammatory diseases.

Job Detail

Type of Contract:  Temporary (36 months): Status: Full-time (40 hours/week)

Specific Requirements for the project

Primary honours degree in Biochemistry, Virology, Immunology or related discipline.

Organisation/Institute

Website: http://a.bergthaler1.at/

 

PROJECT 13

Position is filled

 

 

PROJECT 14

Primary supervisor : Dr. N. Manel, STIMUNITY, Paris, France

Title: To determine how in vivo STING stimulation activates adaptive immune responses

PROJECT: Stimulation of the STING pathway with cyclic dinucleotides such as cGAMP induces a potent immune response in vaccination and in cancer immunotherapy. We and others have discovered that safe Viral-Like Particles (VLP) carry and efficiently deliver cGAMP to immune cells (cGAMP-VLPs). In pre-clinical mouse models, we have shown that cGAMP-VLPs are 1000x more potent than synthetic cyclic dinucleotides at inducing T cell responses against specific antigens. The goal of the PhD is to investigate the unique immunostimulatory properties of cGAMP-VLP at the mechanistic level. In particular, the student will investigate (i) the cell types that receive and directly respond to cGAMP-VLP in vivo, and (ii) the impact of cGAMP-VLPs on cellular physiology (metabolism, autophagy, survival, proliferation) and immune response (activation markers, migration, cytokine expression), in in vitro and in vivo systems. A central question of the PhD is to identity biomarkers of cGAMP-VLP immunogenicity compatible with pre-clinical and clinical settings.

The student will be able to utilize a vast array of experimental approaches already established in the lab (cytometry, microscopy, metabolic analysis, gene expression analysis). The student will also benefit from interactions within the training network, in particular through project-driven secondments in two other partners within the training network.

Job Detail

Type of Contract: Temporary (36 months): Status: Full-time (40 hours/week)

Specific Requirements for the project

We welcome candidates with prior documented expertise in areas such as mouse in vivo experiments, immunology and cytometry, virology in particular retrovirology, molecular cloning, cellular biology and imaging, bioinformatics. The recruited candidate will be selected on the basis of a documented strong prior lab experience and a demonstrable interest in the PhD project.

Organisation/Institute

Websites: https://stimunity.com/

https://science.institut-curie.org/research/integrated-biology/u932-immunity-and-cancer/team-manel/

 

PROJECT 15

Primary supervisor : Dr. R. Zahn, Janssen Vaccines & Prevention B.V. , Leiden, The Netherlands

Title: The determine the influence of immunometabolism pathways in the improvement of mucosal vaccination by adenoviral vectors

PROJECT: Janssen Vaccines is utilizing its adenoviral based vaccine platform in a variety of infectious disease vaccine programs at different stages of clinical development. Janssen has in depth knowledge of adenoviral vector construction, formulation and evaluation of these in established animal (viral disease) models and aims to expand its knowledge on Ad vaccine induced immunity. Viral pathogens that invade via the mucosal route like influenza and respiratory syncytia virus (RSV), or genital route like papilloma virus and Herpes simplex virus (HSV) likely are more efficiently protected against by vaccination that provides a strong immune response at the mucosal point of entry next to a systemic response. Traditional intramuscular vaccination with genetic vaccines may not provide this local protection and/or require additional modulation for optimal mucosal protection. Adenoviral (Ad) vector vaccine delivery by other routes than the intramuscular one has been confirmed to be achievable (Çuburu et al. Int J Cancer 2018) but needs to be explored and characterized in detail. Which cells are targeted after vaccination in these tissues and how the immune response is initiated in contrast to intramuscular vaccination and subsequent triggering of innate and metabolic pathways is not known. Such knowledge will help to better utilize Ad vectors for mucosal vaccination to prevent for example RSV or HSV infection. The high-level approach will consist of exploring additional mucosal routes of vaccination with adenoviral vectors in established animal models. The adaptive local and systemic immune response (like induced innate immune response profile, targeted immune cells in the draining lymph node and site of infection, and metabolic pathway induction) as well as the protective capacity of these novel application routes will be compared to the traditional route of administration. Part of the work will be performed in collaboration with the laboratories of Prof. J Hiscott and Dr. A. Bergthaler. Further in vitro characterization of Ad induced innate and metabolism pathways will be performed to confirm in vivo findings. To optimize dosage via mucosal routes vaccine formulations will be developed in close collaboration with the formulation department at Janssen and tested for in vivo potency.

Job Detail

Type of Contract:  Temporary (24 months+12 month extension); Status: Full-time (40 hours/week)

Specific Requirements for the project

Prospective PhD candidates should have a MSc in Biology, Biomedical Sciences, Immunology, infectious diseases or a related field. They should have knowledge of infectious diseases and the immune system and should be highly motivated to work in a dynamic international team independently.

 

Benefits

Training

ESRs will be part of a vibrant and stimulating international and inter-sectorial collaboration. The INITIATE training programme will equip its ESRs with appropriate scientific and transferable skills, through related and interdependent research projects, interdisciplinary and intersectoral secondments, and network-wide training activities. Scientific training will be supplemented with workshops devoted to academia/industry collaboration, dissemination and public engagement, as well as the maintenance of a successful research environment. ESRs will meet other ESRs involved in the program during the network meetings, secondments and international meetings.

Employment

The successful candidates will be employees of the beneficiary’s institutions, with a contract period of 36 or 48  months, depending on the  length of the PhD program at the hosting institute. The position is funded by a Marie Curie Initial Training Network initiative. The successful candidates will receive an attractive salary in accordance with the Marie Skłodowska-Curie Actions (MSCA) regulations for early stage researchers. The exact salary will be confirmed upon appointment and is dependent on the country correction coefficients (to allow for the difference in cost of living in different EU Member States) as well as applicable regulations. Basic gross rates include a living allowance subject to taxes, social security, employee and employer pension contributions), a mobility allowance and a family allowance. Envisaged job Starting Date: between August 1st 2019 and January1st 2020.

Eligibility criteria

Admission criteria

Candidates must have not been awarded a doctoral degree. Candidates must have excellent proficiency in written and spoken English (at least level B2) and fulfil the specific University recruitment criteria of each position. Candidates can be of any nationality but need to demonstrate mobility in terms of moving  from one country to another when taking up their appointment. Importantly, candidates must not have resided or carried out their activities - work, studies, etc.- in the country of their host organization for more than 12 months in the 3 years immediately before August 1st 2019.

Selection process

Selection

First selection step:

CV’s will be evaluated by the foreseen local supervisors. Numerical scores will be awarded for grading criteria such as relevant studies and experience, study marks, motivation and reference letters.

Second selection step: Foreseen supervisors will have face-to-face or web-based video interviews with candidates. Scoring will be according to background knowledge, dedication, and motivation, based on a semi-quantitative scale. PIs will rank preferred candidates for their project.

Final decisions on the selection of candidates will be made by the primary supervisor and will be finalized during a tele-conference meeting with all PIs. In case of equal-scoring candidates, preference will be given to women and researchers with refugee status (provided they have or are able to obtain work permits).

Additional comments

Positions are open from August 1st  2019, until the positions are filled (at the latest January 1st 2020 ) and ESRs will be based in the Netherlands, Ireland, Norway, Sweden, Austria, France or Italy.

General Data Protection Regulation (GDPR).

INITIATE will process data collected from the applicants for recruitment purposes only, according to the GDPR policies. INITIATE will not share data outside the network, unless upon authorization from the interested applicant. The data will be kept for a period of five years after the end of the project for the purpose of an audit by the EU.

Offer Requirements

  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

We are looking for talented and highly motivated early career researchers educated in biology, infection & immunity, biochemistry or related subjects and experience in cellular biology, (bio)chemistry, immunology and/or virology. We expect dedication and enthusiasm for experimental research, combined with scientific curiosity and the capacity to teamwork in an interdisciplinary environment.

 

Specific Requirements

Candidates must have not been awarded a doctoral degree. Candidates must have excellent proficiency in written and spoken English (at least level B2) and fulfil the specific University recruitment criteria of each position.

Map Information

Work location(s)
2 position(s) available at
Department of Viroscience, Erasmus MC
Netherlands
Rotterdam
3015 CE
's Gravendijkwal 230
2 position(s) available at
Istituto Pasteur-Rome-Sapienza University
Italy
Rome
3 position(s) available at
Trinity College Dublin
Ireland
Dublin
2 position(s) available at
LUMC
Netherlands
Leiden
1 position(s) available at
Norwegian University of Science and Technology
Norway
Trondheim
1 position(s) available at
Virology Division of the Faculty of Veterinary Medicine of Utrecht University
Netherlands
Utrecht
1 position(s) available at
Astrazenca, the IMED Respiratory, Inflammation and Autoimmunity (RIA) unit
Sweden
Gothenburg
1 position(s) available at
The Research Center for Molecular Medicine (CeMM)
Austria
Vienna
1 position(s) available at
Stimunity
France
Paris
1 position(s) available at
Janssen Vaccines & Prevention B.V.
Netherlands
Leiden

Open, Transparent, Merit based Recruitment procedures of Researchers (OTM-R)

Know more about it at ErasmusMC

Know more about OTM-R

EURAXESS offer ID: 400608

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.